<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Non-Small Cell Lung Cancer - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Non-Small Cell Lung Cancer</span>
        </nav>

        <header class="page-header">
            <h1>Non-Small Cell Lung Cancer</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0005233" target="_blank">
                        MONDO:0005233
                    </a>
                </span>
                
                
            </div>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">solid tumor</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Carcinoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Adenosquamous Carcinoma</div>
                
                <div class="item-desc">A rare subtype displaying both adenocarcinoma and squamous cell carcinoma features.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37681230" target="_blank">PMID:37681230</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components."</div>
                
                
                <div class="evidence-explanation">This excerpt confirms that adenosquamous carcinoma displays features of both adenocarcinoma and squamous cell carcinoma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20004040" target="_blank">PMID:20004040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC). ASC are morphologically mixed tumours that contain the two cell components AC and SCC."</div>
                
                
                <div class="evidence-explanation">This literature supports the statement by explaining that adenosquamous carcinoma (ASC) contains both adenocarcinoma (AC) and squamous cell carcinoma (SCC) components.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">ALK-rearranged NSCLC</div>
                
                <div class="item-desc">NSCLC with ALK gene rearrangements, responsive to ALK inhibitors.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27637426" target="_blank">PMID:27637426</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted..."</div>
                
                
                <div class="evidence-explanation">This reference supports that NSCLC with ALK gene rearrangements is a subtype that is responsive to ALK inhibitors.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21233671" target="_blank">PMID:21233671</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The significance of EGFR and ALK mutations in NSCLC and the impact of these genotypes on pathology and clinical practice are also reviewed."</div>
                
                
                <div class="evidence-explanation">This article mentions the impact of ALK mutations and the necessity to identify NSCLCs harboring these mutations due to their sensitivity to specific agents like ALK inhibitors.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24998601" target="_blank">PMID:24998601</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development."</div>
                
                
                <div class="evidence-explanation">This reference discusses the success and approval of ALK inhibitors like Crizotinib and Ceritinib for the treatment of ALK-rearranged NSCLC, supporting the claim.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">EGFR-mutant NSCLC</div>
                
                <div class="item-desc">NSCLC with activating EGFR mutations, responsive to EGFR inhibitors.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28017789" target="_blank">PMID:28017789</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although the most common EGFR mutations-exon 19 deletions or L858R mutations-predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs)..."</div>
                
                
                <div class="evidence-explanation">This excerpt confirms that NSCLC with activating EGFR mutations (such as exon 19 deletions or L858R mutations) are responsive to EGFR TKIs.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15946581" target="_blank">PMID:15946581</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"A genetic mutation in EGFR has also been correlated with an increase in response."</div>
                
                
                <div class="evidence-explanation">This statement supports the idea that NSCLC with EGFR mutations are responsive to EGFR inhibitors.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35993098" target="_blank">PMID:35993098</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Osimertinib is the current standard-of-care for the first-line treatment of EGFR-mutant NSCLC."</div>
                
                
                <div class="evidence-explanation">Osimertinib, an EGFR inhibitor, being the standard-of-care for EGFR-mutant NSCLC indicates that this subtype is responsive to EGFR inhibitors.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oncogenic Driver Mutations</div>
                
                <div class="item-desc">Mutations in genes like EGFR, ALK, ROS1, and BRAF lead to uncontrolled cell growth and survival.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        transmembrane receptor protein tyrosine kinase signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007169" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        MAPK cascade
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000165" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22987962" target="_blank">PMID:22987962</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in EGFR best illustrate the therapeutic relevance of molecular classification. This article reviews the scope of presently known driving molecular alterations, including ROS1, BRAF, KRAS, HER2 and PIK3CA, with a special emphasis on aLK rearrangements, and outlines their potential..."</div>
                
                
                <div class="evidence-explanation">This reference confirms that mutations in genes such as EGFR, ALK, ROS1, and BRAF are recognized as driving molecular alterations that underpin the malignant phenotype of non-small cell lung cancer.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29989448" target="_blank">PMID:29989448</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Activating mutations in the EGFR and rearrangements in the anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) genes have been identified as oncogenic drivers in non-small-cell lung cancer."</div>
                
                
                <div class="evidence-explanation">The reference supports that mutations in EGFR, ALK, and ROS1 genes serve as oncogenic drivers in non-small cell lung cancer, contributing to uncontrolled cell growth and survival.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35709927" target="_blank">PMID:35709927</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The aim of the current study is to extract meaningful information from the online somatic mutation data (retrieved from cBioPortal) of 16 most significantly mutated oncogenes in non-small-cell lung cancer (NSCLC), namely EGFR, NRAS, KRAS, HER2 (ERBB2), RET, MET, ROS1, FGFR1, BRAF ... for..."</div>
                
                
                <div class="evidence-explanation">This reference further lists EGFR, ALK, ROS1, and BRAF among the significantly mutated oncogenes in non-small cell lung cancer, thus supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Immune Evasion</div>
                
                <div class="item-desc">Cancer cells develop mechanisms to evade detection and destruction by the immune system.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        epithelial to mesenchymal transition
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001837" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27416962" target="_blank">PMID:27416962</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We are also beginning to understand the methods of immune evasion employed by NSCLC which likely contribute to the 20% response rate to immunotherapy."</div>
                
                
                <div class="evidence-explanation">The study indicates that non-small cell lung cancer (NSCLC) employs methods of immune evasion, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29107330" target="_blank">PMID:29107330</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. ... Using LOHHLA, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal..."</div>
                
                
                <div class="evidence-explanation">The study describes immune evasion mechanisms such as HLA loss in NSCLC, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37130455" target="_blank">PMID:37130455</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Since MHC-I antigen presentation is not essential for cell growth or survival, many cancers inactivate this pathway, and thereby escape control by CD8 T cells. Such immune evasion allows cancers to progress and also become resistant to CD8 T-cell-based immunotherapies, such as checkpoint blockade."</div>
                
                
                <div class="evidence-explanation">The study discusses how NSCLC cells evade the immune system by inactivating MHC-I antigen presentation, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Angiogenesis</div>
                
                <div class="item-desc">Tumors induce the formation of new blood vessels to support their growth and metastasis.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12824870" target="_blank">PMID:12824870</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Angiogenesis, neovascularization from pre-existing vasculature, is necessary to supply oxygen and nutrition for tumor growth in both primary and distant organs."</div>
                
                
                <div class="evidence-explanation">This reference discusses the requirement of angiogenesis in the growth and metastasis of non-small cell lung cancer (NSCLC).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36269457" target="_blank">PMID:36269457</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pathologic activation of MET can be achieved with increased number of gene copies overexpression, or decreased protein degradation through several mechanisms, including mutations, amplifications, or fusions... Besides its role as primary driver, MET activation might also mediate resistance to..."</div>
                
                
                <div class="evidence-explanation">While the primary focus is not on angiogenesis, it mentions mechanisms of tumor growth and resistance, which can be linked to angiogenesis indirectly.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26222080" target="_blank">PMID:26222080</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Many patients with lung cancer, breast cancer, and melanoma develop brain metastases that are resistant to conventional therapy. The median survival for untreated patients is 1 to 2 months, which may be extended to 6 months with surgery, radiotherapy, and chemotherapy."</div>
                
                
                <div class="evidence-explanation">This reference indirectly supports the statement by talking about brain metastasis and tumor progression but does not specifically focus on angiogenesis.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Tumor Microenvironment Remodeling</div>
                
                <div class="item-desc">Macrophage-dominant immunosuppressive niches with reduced NK and T cell cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux programs that suppress anti-tumor immunity.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        natural killer cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000623" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        fibroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000057" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        regulation of T cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0050863" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Metabolic Rewiring</div>
                
                <div class="item-desc">KRAS/LKB1 co-mutant tumors depend on oxidative pentose phosphate pathway (PPP) via G6PD for NADPH production, redox balance, and lipogenesis; G6PD ablation selectively suppresses tumor growth and activates p53.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        pentose-phosphate shunt
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006098" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        cellular response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034599" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Metastasis</div>
                
                <div class="item-desc">Cancer cells spread from the primary tumor site to distant organs, commonly to the brain, bones, liver, and adrenal glands.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33533174" target="_blank">PMID:33533174</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Our results are suggestive for particular site- and sequence-specific metastasis patterns in human SCLC. SCLC bone metastases tend to appear together with liver metastases, while brain metastases occur together with adrenal gland metastases."</div>
                
                
                <div class="evidence-explanation">While this article primarily deals with small cell lung cancer (SCLC), it does mention metastasis pattern to common sites such as liver and adrenal glands, indicating support for the general concept of lung cancer metastasizing to these distant organs.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31151683" target="_blank">PMID:31151683</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Nearly 75% of patients have a disseminated carcinoma at diagnosis. Up to 50% of patients with a localized disease will develop metastasis. Nevertheless, the current scientific evidence has demonstrated that when the metastatic disease is limited, particularly in specific locations such as the..."</div>
                
                
                <div class="evidence-explanation">This article supports the statement as it mentions that NSCLC can metastasize to the brain and adrenal glands.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23322021" target="_blank">PMID:23322021</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"At least one third of the people with lung cancer develop brain metastases at some point during their disease, even often before the diagnosis of lung cancer is made. The high rate of brain metastasis makes lung cancer the most common type of tumor to spread to the brain."</div>
                
                
                <div class="evidence-explanation">This article further supports the statement by specifying the brain as a common site for metastasis of lung cancer.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">9</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Persistent Cough
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35224703" target="_blank">PMID:35224703</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"A total of 219 NSCLC patients completed the sCSS, Leicester Cough Questionnaire in Mandarin-Chinese (LCQ-MC) and cough Visual Analog Scale (VAS)... The sCSS is a reliable, valid instrument for assessing postoperative cough in NSCLC patients."</div>
                
                
                <div class="evidence-explanation">This study supports that persistent cough is common in NSCLC patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37920959" target="_blank">PMID:37920959</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Persistent cough is one of the most frequent complications following lung cancer surgery. ... Multivariable regression analysis revealed that a duration of anesthesia exceeding 156 min ... and gastroesophageal acid reflux (GER) ... were independent risk factors of persistent CAP."</div>
                
                
                <div class="evidence-explanation">This study confirms the high frequency of persistent cough in patients after lung cancer surgery, aligning with the statement that persistent cough is a common phenotype in NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29666219" target="_blank">PMID:29666219</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Compared with the cough-alone symptom group, the risks of dying or HRs were significantly higher for the groups presenting with breathlessness ..., systemic symptoms ..., weight loss ..., chest pain ..., cough with breathlessness ..., neurological symptoms ... and other symptom combinations ..."</div>
                
                
                <div class="evidence-explanation">While this study shows that cough is one of the symptoms among lung cancer patients, it does not explicitly address the commonality of persistent cough in NSCLC phenotypes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hemoptysis
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002105" target="_blank">
                            HP:0002105
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25359349" target="_blank">PMID:25359349</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Severe haemoptysis due to nonsmall cell lung cancer (NSCLC) is considered a grim condition..."</div>
                
                
                <div class="evidence-explanation">The study confirms that hemoptysis is a recognized condition associated with non-small cell lung cancer (NSCLC).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33563454" target="_blank">PMID:33563454</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"There was no associated hemoptysis, hoarseness, epistaxis, or fever on systemic review."</div>
                
                
                <div class="evidence-explanation">The case report does not support the presence of hemoptysis in the specific instance of NSCLC described.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34807953" target="_blank">PMID:34807953</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"A positive association was observed between scores of respiratory symptoms and deaths due to COPD and lung cancer."</div>
                
                
                <div class="evidence-explanation">The study does not specifically focus on hemoptysis as a symptom of NSCLC.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Weight Loss
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001824" target="_blank">
                            HP:0001824
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35468688" target="_blank">PMID:35468688</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"One of the reasons patients with Non-Small Cell Lung Cancer are not fit for treatment is cancer cachexia, which is common (upto 75% of patients) in this group. This metabolic syndrome presents clinically as weight loss (muscle +/- fat), decreased physical function (patients less active) and..."</div>
                
                
                <div class="evidence-explanation">The literature indicates that weight loss is a common symptom in Non-Small Cell Lung Cancer patients due to cancer cachexia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35559635" target="_blank">PMID:35559635</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Associated symptoms, including hemoptysis or shortness of breath, or systemic symptoms, including anorexia or weight loss, greatly increase the likelihood of having lung cancer."</div>
                
                
                <div class="evidence-explanation">The literature mentions weight loss as a common systemic symptom associated with lung cancer, supporting its prevalence in Non-Small Cell Lung Cancer.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Bone Pain
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002653" target="_blank">
                            HP:0002653
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">May indicate bone metastases</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20536932" target="_blank">PMID:20536932</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bone cancer pain is common in patients with advanced breast, prostate, and lung cancer as these tumors have a remarkable affinity to metastasize to bone."</div>
                
                
                <div class="evidence-explanation">The reference states that bone cancer pain is common in patients with advanced lung cancer, including NSCLC, indicating bone metastases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26690845" target="_blank">PMID:26690845</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer... Bone metastases were evident at diagnosis in 57.5% of patients."</div>
                
                
                <div class="evidence-explanation">This reference discusses the occurrence of bone metastases in NSCLC patients, which is linked to symptoms like bone pain.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38469616" target="_blank">PMID:38469616</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cancer-related fatigue (CRF) stands out as one of the most prevalent subjective adverse reactions experienced by patients following chemotherapy, often resulting in unfavorable symptoms for elderly non-small cell lung cancer (NSCLC) patients during chemotherapy."</div>
                
                
                <div class="evidence-explanation">The study highlights that cancer-related fatigue is a prevalent adverse reaction in elderly NSCLC patients undergoing chemotherapy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33755621" target="_blank">PMID:33755621</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most common adverse effects of treatment are leukopenia, lymphopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, neutropenia, dry skin, stomatitis, fatigue, and cough."</div>
                
                
                <div class="evidence-explanation">Fatigue is listed as one of the most common adverse effects of treatment for NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32013812" target="_blank">PMID:32013812</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"During the early stage, there is no perspicuous sign/symptoms but later many symptoms emerge in the infected individual such as insomnia, headache, pain, loss of appetite, fatigue, coughing etc."</div>
                
                
                <div class="evidence-explanation">Fatigue is mentioned as a symptom that emerges in individuals with lung cancer, including NSCLC.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Bone Pain
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002653" target="_blank">
                            HP:0002653
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">May indicate bone metastases</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26690845" target="_blank">PMID:26690845</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. ... Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy."</div>
                
                
                <div class="evidence-explanation">The reference indicates that bone metastases are common in NSCLC patients, and skeletal-related events are frequent. However, it does not explicitly categorize bone pain as &#39;occasional.&#39;</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20536932" target="_blank">PMID:20536932</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bone cancer pain is common in patients with advanced breast, prostate, and lung cancer as these tumors have a remarkable affinity to metastasize to bone."</div>
                
                
                <div class="evidence-explanation">The reference supports that bone pain is common in lung cancer with bone metastases, but it does not specify the frequency as &#39;occasional.&#39;</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27988895" target="_blank">PMID:27988895</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bone pain arising due to skeletal metastases is one of the common complications experienced by the majority of patients suffering from prostate, breast and lung cancer at the advanced stage of the disease."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement that bone pain is a common complication in advanced lung cancer with skeletal metastases, aligning with the note that it may indicate bone metastases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Chest Pain
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100749" target="_blank">
                            HP:0100749
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27466520" target="_blank">PMID:27466520</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most prevalent symptoms were coughing (EORTC score 41.7), dyspnea (33.9), fatigue (31.9), insomnia (30.3) and pain (21.8)."</div>
                
                
                <div class="evidence-explanation">The study lists pain as one of the prevalent symptoms but does not specify chest pain or its frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20536932" target="_blank">PMID:20536932</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bone cancer pain is common in patients with advanced breast, prostate, and lung cancer as these tumors have a remarkable affinity to metastasize to bone."</div>
                
                
                <div class="evidence-explanation">The study discusses bone cancer pain in the context of lung cancer metastasis but does not mention chest pain or its frequency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Recurrent Pneumonia
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0006532" target="_blank">
                            HP:0006532
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Due to airway obstruction by tumor</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23857204" target="_blank">PMID:23857204</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recurrent pneumonias often occur in the setting of an airway obstruction and can be the presenting symptom of an undiagnosed malignancy."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that recurrent pneumonias often occur due to airway obstruction, which can be a symptom of lung cancer.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15723108" target="_blank">PMID:15723108</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Obstruction of the airway should be initially evaluated with endoscopic procedures."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that airway obstruction, which can be caused by tumors, is a concern in respiratory emergencies in cancer patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Headache
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002315" target="_blank">
                            HP:0002315
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">May indicate brain metastases</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29484515" target="_blank">PMID:29484515</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"However, brain metastasis sometimes occurs in early stage NSCLC patients without any neurological symptoms."</div>
                
                
                <div class="evidence-explanation">The reference indicates that brain metastasis can occur in NSCLC patients, often without neurological symptoms. However, it does not specifically mention headache as an occasional symptom.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11754303" target="_blank">PMID:11754303</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Paraneoplastic disorders may affect any part of the central or peripheral nervous systems."</div>
                
                
                <div class="evidence-explanation">The reference discusses paraneoplastic disorders affecting the nervous system but does not specifically mention headache as a symptom of NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15056056" target="_blank">PMID:15056056</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Brain metastases secondary to primary non-small cell and small cell lung cancer have become an important area of research."</div>
                
                
                <div class="evidence-explanation">The reference discusses brain metastases in NSCLC but does not specifically mention headache as an occasional symptom.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    EGFR
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Activating Mutations)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (7 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23647298" target="_blank">PMID:23647298</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"EGFR mutations are a relatively frequent event in non-small-cell lung cancer, generally consisting of exon 19 deletion or exon 21 substitution. In adenocarcinoma, additional rare mutations are detectable in the EGFR gene."</div>
                
                
                <div class="evidence-explanation">The reference indicates that EGFR mutations, including activating mutations, are a frequent event, which matches the statement that such mutations occur occasionally.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27926500" target="_blank">PMID:27926500</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The results of this study demonstrate that EGFR-TKI therapy results in survival benefits for EGFR-mutant advanced NSCLC patients, regardless of gender, smoking history, pathologic type, type of EGFR mutations, brain metastasis and timing of targeted therapy."</div>
                
                
                <div class="evidence-explanation">This study further supports the association of EGFR activating mutations in NSCLC and the effectiveness of targeted therapies, implying the commonality and impact of these mutations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32107398" target="_blank">PMID:32107398</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"EGFR mutation status might be correlated to CT scans imaging phenotypes."</div>
                
                
                <div class="evidence-explanation">The research recognizes the frequent mutations in EGFR, validating the association stated in the provided statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 4 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ALK
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Gene Rearrangements)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30878128" target="_blank">PMID:30878128</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The ALK receptor tyrosine kinase (ALK) gene encodes a transmembrane protein rearranged in 2-7% of non-small cell lung cancer (NSCLC) cases."</div>
                
                
                <div class="evidence-explanation">The literature describes ALK rearrangements occurring in 2-7% of NSCLC cases, supporting the statement that ALK rearrangements are occasional in frequency in NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35986977" target="_blank">PMID:35986977</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"the presence of ALK/ROS rearrangements in our study is associated with an approximately threefold to fourfold increase in thrombosis risk in NSCLC patients."</div>
                
                
                <div class="evidence-explanation">The mention of ALK rearrangements aligns with the statement indicating that they are a recognised genetic association in NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36806787" target="_blank">PMID:36806787</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"more commonly recognized alterations (such as KRAS, BRAF, MET and ERBB family mutations, or ALK, RET and ROS1 fusions)"</div>
                
                
                <div class="evidence-explanation">The literature identifies ALK rearrangements as part of more commonly recognized alterations/subtypes in NSCLC, supporting their occasional occurrence.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ROS1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Gene Rearrangements)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35200557" target="_blank">PMID:35200557</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"ROS-1 rearrangement is found in 0.9-2.6% of non-small-cell lung cancers (NSCLCs), mostly lung adenocarcinomas."</div>
                
                
                <div class="evidence-explanation">The literature states that ROS-1 rearrangement occurs in a small percentage of NSCLCs, supporting the statement that ROS1 gene rearrangements are occasional in NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35986977" target="_blank">PMID:35986977</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"ROS and ALK rearrangement is highly associated with TE development, with HR of 4.04 ... p = 0.005"</div>
                
                
                <div class="evidence-explanation">The literature mentions ROS1 rearrangements in the context of their association with thromboembolic events, indicating the presence and relevance of these genetic alterations in NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34325210" target="_blank">PMID:34325210</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We investigated the clinical characteristics and gene mutation rate of non-small cell lung cancer patients with osteoblastic bone metastases at the time of the initial diagnosis. ... two were ROS1 rearrangement-positive."</div>
                
                
                <div class="evidence-explanation">This reference confirms the presence of ROS1 rearrangements in a subgroup of NSCLC patients, which aligns with the statement regarding the occasional frequency of these rearrangements.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    KRAS
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Activating Mutations)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33618059" target="_blank">PMID:33618059</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic driver in advanced non-small cell lung cancer, occurring in approximately 30% of lung adenocarcinomas."</div>
                
                
                <div class="evidence-explanation">This reference confirms that KRAS activating mutations are present in non-small cell lung cancer (NSCLC).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23723294" target="_blank">PMID:23723294</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although EGFR mutations were most frequent in patients with ADC and never/light smokers from Asia, and KRAS mutations were most frequent in patients with ADC and ever/heavy smokers from Western countries, both were detected outside these subgroups."</div>
                
                
                <div class="evidence-explanation">This reference supports the occurrence of KRAS mutations in NSCLC, indicating they are within a notable frequency and linked to specific subgroups.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31862576" target="_blank">PMID:31862576</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"KRAS mutations are one of the most prevalent alterations in non-small cell lung cancer."</div>
                
                
                <div class="evidence-explanation">This reference reiterates the frequent nature of KRAS mutations in NSCLC, aligning with the &#34;occasional&#34; frequency stated.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    STK11
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Loss-of-function Mutations)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    KEAP1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Loss-of-function Mutations)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TP53
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Loss-of-function Mutations)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    G6PD
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Metabolic Dependency)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Surgery
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Lobectomy or pneumonectomy for localized disease</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11720753" target="_blank">PMID:11720753</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed. Standard operations include lobectomy,..."</div>
                
                
                <div class="evidence-explanation">This indicates that lobectomy and pneumonectomy are standard surgical treatments for localized non-small cell lung cancer.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37625619" target="_blank">PMID:37625619</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Lobectomy is the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC)."</div>
                
                
                <div class="evidence-explanation">This further reinforces that lobectomy, a type of surgery, is a standard treatment for localized non-small cell lung cancer.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Chemotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12094333" target="_blank">PMID:12094333</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Platinum-based chemotherapy is considered the standard treatment for advanced non-small cell lung cancer (NSCLC). Several phase II trials using cisplatin in combination with new chemotherapeutic agents, such as gemcitabine, the taxanes, vinorelbine, and irinotecan, showed impressive response..."</div>
                
                
                <div class="evidence-explanation">This supports the statement that platinum-based chemotherapy (specifically cisplatin) in combination with other agents is a treatment for NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1329222" target="_blank">PMID:1329222</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"... carboplatin, either alone or in combination, in five separate phase II studies for patients with inoperable non-small cell lung cancer (NSCLC). ... Subsequently, combinations of carboplatin/cisplatin, carboplatin/etoposide, and carboplatin/vinblastine have been evaluated in similar patient groups."</div>
                
                
                <div class="evidence-explanation">This supports the statement as it mentions that carboplatin, either alone or in combination with other agents, is used in the treatment of NSCLC.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26775594" target="_blank">PMID:26775594</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Of the 1564 patients who were included in the prospective study, 1520 received either cisplatin (54%) or carboplatin (46%) in combination with pemetrexed, gemcitabine, taxanes or vinorelbine."</div>
                
                
                <div class="evidence-explanation">The study provides evidence that both cisplatin and carboplatin, in combination with other agents, are used in the treatment of NSCLC.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Targeted Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (8 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34154330" target="_blank">PMID:34154330</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The review article presents the current state and development of the treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer. It focuses on the therapeutic progress of traditionally targeted gene mutations EGFR, ALK and ROS1."</div>
                
                
                <div class="evidence-explanation">The reference discusses EGFR, ALK, and ROS1 inhibitors as targeted therapies for non-small cell lung cancer.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15946581" target="_blank">PMID:15946581</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration."</div>
                
                
                <div class="evidence-explanation">The reference discusses erlotinib and gefitinib as EGFR inhibitors used in the treatment of non-small cell lung cancer.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22932130" target="_blank">PMID:22932130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further."</div>
                
                
                <div class="evidence-explanation">The reference confirms the use of erlotinib (EGFR inhibitor) and crizotinib (ALK and ROS1 inhibitor) in targeted therapy for non-small cell lung cancer.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 5 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Immunotherapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28059852" target="_blank">PMID:28059852</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In accordance with recent results, US Food and Drug Administration approved a checkpoint inhibitor for first-line treatment of metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, and European Medicines Agency approval is expected in early 2017."</div>
                
                
                <div class="evidence-explanation">The FDA has approved immune checkpoint inhibitors for first-line treatment of metastatic NSCLC with high PD-L1 expression, supporting the use of immunotherapy (including nivolumab and pembrolizumab) for these patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26927720" target="_blank">PMID:26927720</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Data so far available show some conflicting results, but PD-L1 immunohistochemistry looks likely to be introduced into clinical use for selecting patients for treatment with anti-PD-1 or anti-PD-L1 therapies."</div>
                
                
                <div class="evidence-explanation">The mention of PD-L1 immunohistochemistry being introduced for clinically selecting patients for anti-PD-1 therapies supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32189549" target="_blank">PMID:32189549</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control."</div>
                
                
                <div class="evidence-explanation">While it shows the effectiveness of checkpoint inhibitors, it is about treatment beyond progression and does not specifically address high PD-L1 expression.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Radiation Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000014" target="_blank">
                            MAXO:0000014
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used for localized disease, palliation of symptoms, or brain metastases</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7540125" target="_blank">PMID:7540125</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"recent notable developments have occurred involving radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC)... For palliation of tumor-related symptoms... metastases to the adrenal gland, liver, and subcutaneous tissues can be palliated successfully by brief courses of RT...."</div>
                
                
                <div class="evidence-explanation">Supports the use of RT for palliation of symptoms and metastatic sites, but does not specifically mention its use for localized disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8853542" target="_blank">PMID:8853542</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"In the palliation of non-small cell lung cancer... in the management of chest disease, bone metastases, and brain metastases."</div>
                
                
                <div class="evidence-explanation">Supports the use of RT in palliation of symptoms and brain metastases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32140986" target="_blank">PMID:32140986</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Concurrent chemoradiation is the cornerstone of treatment of unresectable, locally advanced NSCLC."</div>
                
                
                <div class="evidence-explanation">Supports the use of RT for locally advanced (localized) disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Smoking</div>
                
                <div class="item-desc">Major risk factor, particularly for squamous cell carcinoma</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27188576" target="_blank">PMID:27188576</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Non-small-cell lung cancer (NSCLC), a heterogeneous class of tumours, represents approximately 85% of all new lung cancer diagnoses. Tobacco smoking remains the main risk factor for developing this disease."</div>
                
                
                <div class="evidence-explanation">This reference explicitly mentions tobacco smoking as the main risk factor for non-small cell lung cancer.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24976334" target="_blank">PMID:24976334</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The never-smokers had a significantly better prognosis than ever-smokers among Ad patients, whereas the light-smokers had a significantly worse prognosis than heavy smokers among Sq patients."</div>
                
                
                <div class="evidence-explanation">This study emphasizes the relationship between smoking and prognosis in different types of NSCLC, indicating that smoking is a significant factor.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9498897" target="_blank">PMID:9498897</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Tobacco smoke has been shown to increase the risk of lung cancer down to the lowest exposure levels. Environmental tobacco smoke contains the same carcinogenic compounds as those found in the tobacco smoke inhaled directly by the smoker."</div>
                
                
                <div class="evidence-explanation">This reference discusses the carcinogenic effects of tobacco smoke, affirming its role as a risk factor for lung cancer.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Radon Exposure</div>
                
                <div class="item-desc">Increases risk, especially in combination with smoking</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12075673" target="_blank">PMID:12075673</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Based on the most recent findings, there is some evidence that radon may contribute to lung cancer risk in current smokers in high residential radon environments... The situation regarding the risk of lung cancer from radon in non-smokers (ex and never) is unclear."</div>
                
                
                <div class="evidence-explanation">There is evidence that radon exposure may increase lung cancer risk in smokers, but the evidence for non-smokers is unclear.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38159450" target="_blank">PMID:38159450</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Miners increased risk of contracting lung cancer is included. It is concluded that the mine ventilation system satisfies the conditions required by the current radiological protection of the miners."</div>
                
                
                <div class="evidence-explanation">This study discusses the increased risk of lung cancer associated with radon exposure for underground workers, which supports the link between radon and lung cancer risk.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20429156" target="_blank">PMID:20429156</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Environmental factors in cancer... radon."</div>
                
                
                <div class="evidence-explanation">The provided literature does not contain any detailed content to evaluate the support of the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Carcinoembryonic Antigen
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37390106" target="_blank">PMID:37390106</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carcinoembryonic antigen (CEA) is the most frequently used tumor marker for non-small cell lung cancer (NSCLC)."</div>
                
                
                <div class="evidence-explanation">The reference discusses the use of CEA as a tumor marker in NSCLC, indicating its relevance and occasional elevated presence.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Cytokeratin Fragment 21-1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8709175" target="_blank">PMID:8709175</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The mean (SD) value of serum CYFRA 21-1 in NSCLC (13.26 (16.54)) was significantly higher than in benign lung diseases (1.74 (1.55)) (p &lt; 0.0001)."</div>
                
                
                <div class="evidence-explanation">CYFRA 21-1 levels are elevated in NSCLC patients, supporting the statement of its occasional presence in a biochemical context.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0f2fe; color: #0284c7;">üìä</div>
                <h2 class="card-title">Related Datasets</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box dataset-box">
                <div class="item-name">
                    Single cell RNA sequencing of lung adenocarcinoma
                    
                    <span class="dataset-accession">
                        <a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131907" target="_blank">geo:GSE131907</a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Large-scale single-cell RNA sequencing from 11 adjacent normal and 15 tumor tissue samples from NSCLC patients (stages I-IV). After quality filtering, 98,504 cells retained including 16,046 epithelial, 5,468 stromal, and 76,990 immune cells.</div>
                
                <div class="item-meta">
                    
                    <span class="tag tag-organism">human</span>
                    
                    
                    <span class="tag tag-datatype">SINGLE CELL RNA SEQ</span>
                    
                    
                    <span class="tag tag-dataset">n=26</span>
                    
                    
                </div>
                
                <div class="item-meta" style="margin-top: 6px;">
                    
                    <span class="tag tag-cell">
                        lung tumor tissue
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta" style="margin-top: 6px;">
                    <strong style="font-size: 0.8rem; color: #0369a1;">Conditions:</strong>
                    
                    <span class="tag" style="background: #f0f9ff; color: #0369a1; font-size: 0.8rem;">NSCLC tumor tissue</span>
                    
                    <span class="tag" style="background: #f0f9ff; color: #0369a1; font-size: 0.8rem;">adjacent normal lung tissue</span>
                    
                </div>
                
                
                
                
                <div class="item-desc" style="margin-top: 8px; font-style: italic;">Comprehensive single-cell atlas identifying eight major cell types. Resolves tumor-infiltrating immune cell heterogeneity relevant to immunotherapy response. Part of integrated NSCLC scRNA-seq resource.</div>
                
                
    
    
            </div>
            
            <div class="item-box dataset-box">
                <div class="item-name">
                    Comprehensive transcriptomic profiles of non-small cell lung cancer by single-cell RNA-seq
                    
                    <span class="dataset-accession">
                        <a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119911" target="_blank">geo:GSE119911</a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Single-cell RNA sequencing profiling over 9,000 individual cells from tumor and adjacent normal tissues of 20 patients with stage I-IV NSCLC using modified STRT-seq technique.</div>
                
                <div class="item-meta">
                    
                    <span class="tag tag-organism">human</span>
                    
                    
                    <span class="tag tag-datatype">SINGLE CELL RNA SEQ</span>
                    
                    
                    <span class="tag tag-dataset">n=106</span>
                    
                    
                </div>
                
                <div class="item-meta" style="margin-top: 6px;">
                    
                    <span class="tag tag-cell">
                        lung tumor tissue
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta" style="margin-top: 6px;">
                    <strong style="font-size: 0.8rem; color: #0369a1;">Conditions:</strong>
                    
                    <span class="tag" style="background: #f0f9ff; color: #0369a1; font-size: 0.8rem;">NSCLC tumor tissue</span>
                    
                    <span class="tag" style="background: #f0f9ff; color: #0369a1; font-size: 0.8rem;">adjacent normal tissue</span>
                    
                </div>
                
                
                
                
                <div class="item-desc" style="margin-top: 8px; font-style: italic;">Characterizes inter-patient and intra-tumor heterogeneity including epithelial, stromal, and immune cell compartments. Useful for understanding cancer progression and therapeutic strategies</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Non-Small Cell Lung Cancer
synonyms:
- NSCLC
categories:
- Lung Cancer
- Respiratory Malignancy
has_subtypes:
- name: Adenosquamous Carcinoma
  description: A rare subtype displaying both adenocarcinoma and squamous cell carcinoma
    features.
  evidence:
  - reference: PMID:37681230
    supports: SUPPORT
    snippet: Adenosquamous carcinoma of the lung is a characteristic tumor that has
      both adenocarcinoma and squamous cell carcinoma components.
    explanation: This excerpt confirms that adenosquamous carcinoma displays features
      of both adenocarcinoma and squamous cell carcinoma.
  - reference: PMID:20004040
    supports: SUPPORT
    snippet: Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous
      carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas
      (NSCLC). ASC are morphologically mixed tumours that contain the two cell components
      AC and SCC.
    explanation: This literature supports the statement by explaining that adenosquamous
      carcinoma (ASC) contains both adenocarcinoma (AC) and squamous cell carcinoma
      (SCC) components.
- name: ALK-rearranged NSCLC
  description: NSCLC with ALK gene rearrangements, responsive to ALK inhibitors.
  evidence:
  - reference: PMID:27637426
    supports: SUPPORT
    snippet: An early result of this search was the discovery of NSCLC driven by activating
      rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly
      brief period following the recognition of ALK-positive NSCLC, details of the
      biology, clinicopathologic features, development of targeted inhibitors, mechanisms
      of therapeutic resistance, and new generations of treatment were elucidated.
    explanation: This reference supports that NSCLC with ALK gene rearrangements is
      a subtype that is responsive to ALK inhibitors.
  - reference: PMID:21233671
    supports: SUPPORT
    snippet: The significance of EGFR and ALK mutations in NSCLC and the impact of
      these genotypes on pathology and clinical practice are also reviewed.
    explanation: This article mentions the impact of ALK mutations and the necessity
      to identify NSCLCs harboring these mutations due to their sensitivity to specific
      agents like ALK inhibitors.
  - reference: PMID:24998601
    supports: SUPPORT
    snippet: The accelerated approval of the first ALK-inhibitor, Crizotinib and more
      recently Ceritinib, without a Phase III randomized, clinical trial, has been
      an amazing success story in lung cancer research, marking the beginning of a
      new decade of targeted drugs development.
    explanation: This reference discusses the success and approval of ALK inhibitors
      like Crizotinib and Ceritinib for the treatment of ALK-rearranged NSCLC, supporting
      the claim.
  - reference: PMID:31720561
    supports: SUPPORT
    snippet: Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients
      with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most
      cases, adenocarcinoma is the dominant histology.
    explanation: This indirectly supports that ALK-rearranged NSCLC is a recognized
      subtype as it compares ROS1+ NSCLC to ALK-positive NSCLC in terms of patient
      characteristics and histology.
  - reference: PMID:33387080
    supports: SUPPORT
    snippet: Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event
      in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting
      represents the main therapeutic strategy.
    explanation: This recent review discusses the targeting of ALK rearrangements
      as a therapeutic strategy, supporting that ALK-rearranged NSCLC is a recognized
      subtype responsive to ALK inhibitors.
- name: EGFR-mutant NSCLC
  description: NSCLC with activating EGFR mutations, responsive to EGFR inhibitors.
  evidence:
  - reference: PMID:28017789
    supports: SUPPORT
    snippet: Although the most common EGFR mutations-exon 19 deletions or L858R mutations-predict
      sensitivity to EGFR tyrosine kinase inhibitors (TKIs)...
    explanation: This excerpt confirms that NSCLC with activating EGFR mutations (such
      as exon 19 deletions or L858R mutations) are responsive to EGFR TKIs.
  - reference: PMID:15946581
    supports: SUPPORT
    snippet: A genetic mutation in EGFR has also been correlated with an increase
      in response.
    explanation: This statement supports the idea that NSCLC with EGFR mutations are
      responsive to EGFR inhibitors.
  - reference: PMID:35993098
    supports: SUPPORT
    snippet: Osimertinib is the current standard-of-care for the first-line treatment
      of EGFR-mutant NSCLC.
    explanation: Osimertinib, an EGFR inhibitor, being the standard-of-care for EGFR-mutant
      NSCLC indicates that this subtype is responsive to EGFR inhibitors.
  - reference: PMID:24857124
    supports: SUPPORT
    snippet: Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and
      L858R substitutions) are the most robust predictive biomarker for symptom improvement,
      radiographic response, and increment in progression-free survival (PFS) when
      EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced
      NSCLC.
    explanation: This excerpt specifically notes the responsiveness of NSCLC with
      TKI-sensitizing EGFR mutations to EGFR inhibitors.
  - reference: PMID:25145405
    supports: SUPPORT
    snippet: Several large Phase III trials have shown that EGFR-TKIs improved the
      progression-free survival of patients with EGFR mutant NSCLC compared to conventional
      chemotherapy.
    explanation: This indicates the effectiveness of EGFR inhibitors in treating EGFR-mutant
      NSCLC.
progression:
- phase: Onset
  age_range: 60-80
  evidence:
  - reference: PMID:15477641
    supports: NO_EVIDENCE
    snippet: What is clear is that currently over 50% of all patients with non-small
      cell lung cancer (NSCLC) are 65 years of age or older.
    explanation: The study mentions the prevalence of NSCLC in patients aged 65 and
      older, but it does not directly address disease progression specifically in
      the 60-80 age range at the onset phase.
  - reference: PMID:20471184
    supports: NO_EVIDENCE
    snippet: To assess rate of disease progression from diagnosis to initiation of
      treatment for Stage I-IIIB non-small-cell lung cancer (NSCLC).
    explanation: This study addresses the rate of disease progression from diagnosis
      to treatment initiation rather than focusing on age-specific progression at
      onset.
  - reference: PMID:38377969
    supports: NO_EVIDENCE
    snippet: The objective of this study was to model multiple sclerosis (MS) disease
      progression and compare disease trajectories by sex, age of onset, and year
      of diagnosis.
    explanation: The study focuses on multiple sclerosis and not on non-small cell
      lung cancer.
  - reference: PMID:37681230
    supports: NO_EVIDENCE
    snippet: Adenosquamous carcinoma of the lung is a characteristic tumor that has
      both adenocarcinoma and squamous cell carcinoma components.
    explanation: This study focuses on adenosquamous carcinoma and does not address
      age-specific progression of NSCLC in the 60-80 age range specifically at onset.
  - reference: PMID:34911717
    supports: NO_EVIDENCE
    snippet: To assess clinicopathological predictors and prognosis in early-onset
      colorectal cancer (CRC) in Lynch syndrome with comparison to patients diagnosed
      from age 40 and up.
    explanation: The study is about early-onset colorectal cancer in patients with
      Lynch syndrome and is not related to NSCLC.
  - reference: PMID:26729443
    supports: NO_EVIDENCE
    snippet: Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon
      14 and its flanking introns may respond to c-Met inhibitors.
    explanation: While the study addresses genomic characteristics and treatment responses
      for NSCLC with MET exon 14 mutations, it does not specifically discuss disease
      progression at onset in the 60-80 age range.
  - reference: PMID:29432718
    supports: NO_EVIDENCE
    snippet: Among patients with previous lung cancer, the malignant potential of
      subsequent ground-glass opacities (GGOs) on computed tomography remains unknown.
    explanation: The study examines ground-glass opacities among patients with a history
      of lung cancer, not specifically the progression of NSCLC in the 60-80 age range
      at onset.
pathophysiology:
- name: Oncogenic Driver Mutations
  description: Mutations in genes like EGFR, ALK, ROS1, and BRAF lead to uncontrolled
    cell growth and survival.
  biological_processes:
  - preferred_term: transmembrane receptor protein tyrosine kinase signaling pathway
    description: Dysregulated RTK signaling via EGFR, ALK, MET drives proliferation
      and survival
    term:
      id: GO:0007169
      label: transmembrane receptor protein tyrosine kinase signaling pathway
  - preferred_term: MAPK cascade
    description: Constitutive MAPK activation via KRAS, EGFR, ALK mutations
    term:
      id: GO:0000165
      label: MAPK cascade
  evidence:
  - reference: PMID:22987962
    supports: SUPPORT
    snippet: Mutations in EGFR best illustrate the therapeutic relevance of molecular
      classification. This article reviews the scope of presently known driving molecular
      alterations, including ROS1, BRAF, KRAS, HER2 and PIK3CA, with a special emphasis
      on aLK rearrangements, and outlines their potential therapeutic applications.
    explanation: This reference confirms that mutations in genes such as EGFR, ALK,
      ROS1, and BRAF are recognized as driving molecular alterations that underpin
      the malignant phenotype of non-small cell lung cancer.
  - reference: PMID:29989448
    supports: SUPPORT
    snippet: Activating mutations in the EGFR and rearrangements in the anaplastic
      lymphoma kinase (ALK) or ROS proto-oncogene 1 receptor tyrosine kinase (ROS1)
      genes have been identified as oncogenic drivers in non-small-cell lung cancer.
    explanation: The reference supports that mutations in EGFR, ALK, and ROS1 genes
      serve as oncogenic drivers in non-small cell lung cancer, contributing to uncontrolled
      cell growth and survival.
  - reference: PMID:35709927
    supports: SUPPORT
    snippet: The aim of the current study is to extract meaningful information from
      the online somatic mutation data (retrieved from cBioPortal) of 16 most significantly
      mutated oncogenes in non-small-cell lung cancer (NSCLC), namely EGFR, NRAS,
      KRAS, HER2 (ERBB2), RET, MET, ROS1, FGFR1, BRAF ... for improving our understanding
      of the pathobiology of the lung cancer.
    explanation: This reference further lists EGFR, ALK, ROS1, and BRAF among the
      significantly mutated oncogenes in non-small cell lung cancer, thus supporting
      the statement.
  - reference: PMID:31627700
    supports: SUPPORT
    snippet: Epidermal growth factor receptor (EGFR) mutations play an important role
      in the pathogenesis of non-small cell lung cancer. ... In patients with EGFR
      mutations, a significant improvement in therapeutic outcomes was achieved with
      the administration of targeted therapy using tyrosine kinase inhibitors.
    explanation: This reference confirms the crucial role of EGFR mutations in NSCLC
      pathogenesis, indicating their role in driving tumor growth and survival.
  - reference: PMID:33435440
    supports: SUPPORT
    snippet: Testing the presence of driver mutations in specific genes in lung tumors
      has thus radically changed the clinical management and outcomes of the disease.
      ... namely EGFR, KRAS, BRAF, MET, and HER2 mutations or amplification, as well
      as ALK and ROS1 fusions.
    explanation: This reference supports that identifying driver mutations in genes
      like EGFR, ALK, ROS1, and BRAF is crucial in the clinical management of NSCLC,
      implying their role in uncontrolled cell growth and survival.
- name: Immune Evasion
  description: Cancer cells develop mechanisms to evade detection and destruction
    by the immune system.
  biological_processes:
  - preferred_term: epithelial to mesenchymal transition
    description: EMT programs linked to immune suppression and therapy resistance;
      EGFR-mutant tumors may transform to SCLC
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
  evidence:
  - reference: PMID:27416962
    supports: SUPPORT
    snippet: We are also beginning to understand the methods of immune evasion employed
      by NSCLC which likely contribute to the 20% response rate to immunotherapy.
    explanation: The study indicates that non-small cell lung cancer (NSCLC) employs
      methods of immune evasion, which aligns with the statement.
  - reference: PMID:29107330
    supports: SUPPORT
    snippet: Immune evasion is a hallmark of cancer. Losing the ability to present
      neoantigens through human leukocyte antigen (HLA) loss may facilitate immune
      evasion. ... Using LOHHLA, we find that HLA LOH occurs in 40% of non-small-cell
      lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden,
      APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity.
    explanation: The study describes immune evasion mechanisms such as HLA loss in
      NSCLC, supporting the statement.
  - reference: PMID:37130455
    supports: SUPPORT
    snippet: Since MHC-I antigen presentation is not essential for cell growth or
      survival, many cancers inactivate this pathway, and thereby escape control by
      CD8 T cells. Such immune evasion allows cancers to progress and also become
      resistant to CD8 T-cell-based immunotherapies, such as checkpoint blockade.
    explanation: The study discusses how NSCLC cells evade the immune system by inactivating
      MHC-I antigen presentation, supporting the statement.
  - reference: PMID:34484217
    supports: SUPPORT
    snippet: These data raise the possibility that proteins with mechanical barrier
      function in NSCLC may be used by cancer cells to protect them from immune cell
      infiltration and immune-mediated destruction, which can otherwise be targeted
      effectively with immunotherapy or collagen therapy.
    explanation: The study mentions mechanisms employed by NSCLC cells to evade immune
      destruction, supporting the statement.
  - reference: PMID:37086716
    supports: SUPPORT
    snippet: These data demonstrate that enhanced TRM-like activity prior to tumor
      development shapes the evolution of tumor immunogenicity and can impact immunotherapy
      outcomes.
    explanation: The study outlines mechanisms of immune evasion in NSCLC, such as
      the loss of MHC class I protein expression, supporting the statement.
- name: Angiogenesis
  description: Tumors induce the formation of new blood vessels to support their growth
    and metastasis.
  evidence:
  - reference: PMID:12824870
    supports: SUPPORT
    snippet: Angiogenesis, neovascularization from pre-existing vasculature, is necessary
      to supply oxygen and nutrition for tumor growth in both primary and distant
      organs.
    explanation: This reference discusses the requirement of angiogenesis in the growth
      and metastasis of non-small cell lung cancer (NSCLC).
  - reference: PMID:36269457
    supports: PARTIAL
    snippet: Pathologic activation of MET can be achieved with increased number of
      gene copies overexpression, or decreased protein degradation through several
      mechanisms, including mutations, amplifications, or fusions... Besides its role
      as primary driver, MET activation might also mediate resistance to kinase inhibitors
      in NSCLC with various other actionable alterations.
    explanation: While the primary focus is not on angiogenesis, it mentions mechanisms
      of tumor growth and resistance, which can be linked to angiogenesis indirectly.
  - reference: PMID:26222080
    supports: PARTIAL
    snippet: Many patients with lung cancer, breast cancer, and melanoma develop brain
      metastases that are resistant to conventional therapy. The median survival for
      untreated patients is 1 to 2 months, which may be extended to 6 months with
      surgery, radiotherapy, and chemotherapy.
    explanation: This reference indirectly supports the statement by talking about
      brain metastasis and tumor progression but does not specifically focus on angiogenesis.
  - reference: PMID:22550239
    supports: NO_EVIDENCE
    snippet: Lung cancer, of which non-small cell lung cancer (NSCLC) composes the
      majority, is the leading cause of cancer-related deaths in the United States
      and worldwide... field cancerization phenomenon...
    explanation: The reference discusses field cancerization and the complexities
      of NSCLC but does not provide specific evidence related to angiogenesis.
- name: Tumor Microenvironment Remodeling
  description: Macrophage-dominant immunosuppressive niches with reduced NK and T cell
    cytotoxicity; tumor-associated macrophages adopt cholesterol export and iron efflux
    programs that suppress anti-tumor immunity.
  notes: Single-cell spatial mapping reveals inverse relationship between anti-inflammatory
    macrophages and NK/T cells
  cell_types:
  - preferred_term: macrophage
    description: Tumor-associated macrophages (TAMs) reprogrammed to cholesterol export
      and iron efflux states; dominant immunosuppressive population
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T cell
    description: Reduced T cell infiltration and cytotoxicity in immunosuppressive
      niches; altered checkpoint co-expression patterns
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: natural killer cell
    description: Reduced NK cell cytotoxicity; inverse relationship with anti-inflammatory
      macrophages
    term:
      id: CL:0000623
      label: natural killer cell
  - preferred_term: fibroblast
    description: Cancer-associated fibroblasts (CAFs) contribute to immunosuppressive
      niches and stromal remodeling
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: regulation of T cell activation
    description: Altered T cell activation in TME; checkpoint co-expression patterns;
      dual ICI modulates CD4+ responses
    term:
      id: GO:0050863
      label: regulation of T cell activation
  locations:
  - preferred_term: parenchyma of lung
    description: Primary site of TME remodeling
    term:
      id: UBERON:0008946
      label: parenchyma of lung
- name: Metabolic Rewiring
  description: KRAS/LKB1 co-mutant tumors depend on oxidative pentose phosphate pathway
    (PPP) via G6PD for NADPH production, redox balance, and lipogenesis; G6PD ablation
    selectively suppresses tumor growth and activates p53.
  notes: Represents a therapeutically exploitable metabolic vulnerability in KRAS/LKB1
    tumors
  biological_processes:
  - preferred_term: pentose-phosphate shunt
    description: KRAS/LKB1 tumors depend on oxidative PPP via G6PD for NADPH and
      lipogenesis
    term:
      id: GO:0006098
      label: pentose-phosphate shunt
  - preferred_term: cellular response to oxidative stress
    description: G6PD impairment disrupts redox balance and activates p53
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
- name: Metastasis
  description: Cancer cells spread from the primary tumor site to distant organs,
    commonly to the brain, bones, liver, and adrenal glands.
  evidence:
  - reference: PMID:33533174
    supports: SUPPORT
    snippet: Our results are suggestive for particular site- and sequence-specific
      metastasis patterns in human SCLC. SCLC bone metastases tend to appear together
      with liver metastases, while brain metastases occur together with adrenal gland
      metastases.
    explanation: While this article primarily deals with small cell lung cancer (SCLC),
      it does mention metastasis pattern to common sites such as liver and adrenal
      glands, indicating support for the general concept of lung cancer metastasizing
      to these distant organs.
  - reference: PMID:31151683
    supports: SUPPORT
    snippet: Nearly 75% of patients have a disseminated carcinoma at diagnosis. Up
      to 50% of patients with a localized disease will develop metastasis. Nevertheless,
      the current scientific evidence has demonstrated that when the metastatic disease
      is limited, particularly in specific locations such as the brain and the adrenal
      glands, a multidisciplinary approach with radical intent could achieve a longer
      survival.
    explanation: This article supports the statement as it mentions that NSCLC can
      metastasize to the brain and adrenal glands.
  - reference: PMID:23322021
    supports: SUPPORT
    snippet: At least one third of the people with lung cancer develop brain metastases
      at some point during their disease, even often before the diagnosis of lung
      cancer is made. The high rate of brain metastasis makes lung cancer the most
      common type of tumor to spread to the brain.
    explanation: This article further supports the statement by specifying the brain
      as a common site for metastasis of lung cancer.
  - reference: PMID:36269457
    supports: SUPPORT
    snippet: Pathologic activation of MET can be achieved with increased number of
      gene copies overexpression, or decreased protein degradation through several
      mechanisms, including mutations, amplifications, or fusions. Besides its role
      as primary driver, MET activation might also mediate resistance to kinase inhibitors
      in NSCLC with various other actionable alterations.
    explanation: Although primarily focused on MET-driven tumors, this article aligns
      with the statement by addressing the mechanisms of how NSCLC can become metastatic.
histopathology:
- name: Mixed NSCLC Histology
  frequency: VERY_FREQUENT
  description: &gt;-
    Non-small cell lung cancers include adenocarcinoma and squamous cell carcinoma patterns,
    with adenocarcinoma most common.

phenotypes:
- category: Respiratory
  name: Persistent Cough
  frequency: FREQUENT
  evidence:
  - reference: PMID:35224703
    supports: SUPPORT
    snippet: A total of 219 NSCLC patients completed the sCSS, Leicester Cough Questionnaire
      in Mandarin-Chinese (LCQ-MC) and cough Visual Analog Scale (VAS)... The sCSS
      is a reliable, valid instrument for assessing postoperative cough in NSCLC patients.
    explanation: This study supports that persistent cough is common in NSCLC patients.
  - reference: PMID:37920959
    supports: SUPPORT
    snippet: Persistent cough is one of the most frequent complications following
      lung cancer surgery. ... Multivariable regression analysis revealed that a duration
      of anesthesia exceeding 156 min ... and gastroesophageal acid reflux (GER) ...
      were independent risk factors of persistent CAP.
    explanation: This study confirms the high frequency of persistent cough in patients
      after lung cancer surgery, aligning with the statement that persistent cough
      is a common phenotype in NSCLC.
  - reference: PMID:29666219
    supports: PARTIAL
    snippet: Compared with the cough-alone symptom group, the risks of dying or HRs
      were significantly higher for the groups presenting with breathlessness ...,
      systemic symptoms ..., weight loss ..., chest pain ..., cough with breathlessness
      ..., neurological symptoms ... and other symptom combinations ...
    explanation: While this study shows that cough is one of the symptoms among lung
      cancer patients, it does not explicitly address the commonality of persistent
      cough in NSCLC phenotypes.
- category: Respiratory
  name: Hemoptysis
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:25359349
    supports: SUPPORT
    snippet: Severe haemoptysis due to nonsmall cell lung cancer (NSCLC) is considered
      a grim condition...
    explanation: The study confirms that hemoptysis is a recognized condition associated
      with non-small cell lung cancer (NSCLC).
  - reference: PMID:33563454
    supports: NO_EVIDENCE
    snippet: There was no associated hemoptysis, hoarseness, epistaxis, or fever on
      systemic review.
    explanation: The case report does not support the presence of hemoptysis in the
      specific instance of NSCLC described.
  - reference: PMID:34807953
    supports: NO_EVIDENCE
    snippet: A positive association was observed between scores of respiratory symptoms
      and deaths due to COPD and lung cancer.
    explanation: The study does not specifically focus on hemoptysis as a symptom
      of NSCLC.
  phenotype_term:
    preferred_term: Hemoptysis
    term:
      id: HP:0002105
      label: Hemoptysis
- category: Systemic
  name: Weight Loss
  frequency: FREQUENT
  evidence:
  - reference: PMID:35468688
    supports: SUPPORT
    snippet: One of the reasons patients with Non-Small Cell Lung Cancer are not fit
      for treatment is cancer cachexia, which is common (upto 75% of patients) in
      this group. This metabolic syndrome presents clinically as weight loss (muscle
      +/- fat), decreased physical function (patients less active) and anorexia on
      a background of systemic inflammation.
    explanation: The literature indicates that weight loss is a common symptom in
      Non-Small Cell Lung Cancer patients due to cancer cachexia.
  - reference: PMID:35559635
    supports: SUPPORT
    snippet: Associated symptoms, including hemoptysis or shortness of breath, or
      systemic symptoms, including anorexia or weight loss, greatly increase the likelihood
      of having lung cancer.
    explanation: The literature mentions weight loss as a common systemic symptom
      associated with lung cancer, supporting its prevalence in Non-Small Cell Lung
      Cancer.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Musculoskeletal
  name: Bone Pain
  frequency: OCCASIONAL
  notes: May indicate bone metastases
  evidence:
  - reference: PMID:20536932
    supports: SUPPORT
    snippet: Bone cancer pain is common in patients with advanced breast, prostate,
      and lung cancer as these tumors have a remarkable affinity to metastasize to
      bone.
    explanation: The reference states that bone cancer pain is common in patients
      with advanced lung cancer, including NSCLC, indicating bone metastases.
  - reference: PMID:26690845
    supports: SUPPORT
    snippet: We conducted a large, multicenter, retrospective survey aimed to explore
      the impact of tumor bone involvement in Non-Small Cell Lung Cancer... Bone metastases
      were evident at diagnosis in 57.5% of patients.
    explanation: This reference discusses the occurrence of bone metastases in NSCLC
      patients, which is linked to symptoms like bone pain.
  phenotype_term:
    preferred_term: Bone Pain
    term:
      id: HP:0002653
      label: Bone pain
- category: Systemic
  frequency: FREQUENT
  name: Fatigue
  evidence:
  - reference: PMID:38469616
    supports: SUPPORT
    snippet: Cancer-related fatigue (CRF) stands out as one of the most prevalent
      subjective adverse reactions experienced by patients following chemotherapy,
      often resulting in unfavorable symptoms for elderly non-small cell lung cancer
      (NSCLC) patients during chemotherapy.
    explanation: The study highlights that cancer-related fatigue is a prevalent adverse
      reaction in elderly NSCLC patients undergoing chemotherapy.
  - reference: PMID:33755621
    supports: SUPPORT
    snippet: The most common adverse effects of treatment are leukopenia, lymphopenia,
      thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity,
      neutropenia, dry skin, stomatitis, fatigue, and cough.
    explanation: Fatigue is listed as one of the most common adverse effects of treatment
      for NSCLC.
  - reference: PMID:32013812
    supports: SUPPORT
    snippet: During the early stage, there is no perspicuous sign/symptoms but later
      many symptoms emerge in the infected individual such as insomnia, headache,
      pain, loss of appetite, fatigue, coughing etc.
    explanation: Fatigue is mentioned as a symptom that emerges in individuals with
      lung cancer, including NSCLC.
  - reference: PMID:26990789
    supports: SUPPORT
    snippet: Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhea,
      nausea and vomiting, rash, bleeding, hypertension, and hair loss.
    explanation: Fatigue is listed as one of the common grade III/IV toxicities associated
      with treatment for metastatic NSCLC.
  - reference: PMID:30537755
    supports: SUPPORT
    snippet: Non-hematological toxicities of &gt;/= grade 2 included anorexia (27.5%)
      and fatigue (24.6%).
    explanation: Fatigue is noted as a non-hematological toxicity in NSCLC patients
      beyond third-line therapy.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Bone Pain
  notes: May indicate bone metastases
  evidence:
  - reference: PMID:26690845
    supports: PARTIAL
    snippet: Bone metastases were evident at diagnosis in 57.5% of patients. In the
      remaining cases median time to bone metastases appearance was 9 months. ...
      Skeletal-related events were experienced by 57.7% of patients; the most common
      was the need for radiotherapy.
    explanation: The reference indicates that bone metastases are common in NSCLC
      patients, and skeletal-related events are frequent. However, it does not explicitly
      categorize bone pain as &#39;occasional.&#39;
  - reference: PMID:20536932
    supports: PARTIAL
    snippet: Bone cancer pain is common in patients with advanced breast, prostate,
      and lung cancer as these tumors have a remarkable affinity to metastasize to
      bone.
    explanation: The reference supports that bone pain is common in lung cancer with
      bone metastases, but it does not specify the frequency as &#39;occasional.&#39;
  - reference: PMID:27988895
    supports: SUPPORT
    snippet: Bone pain arising due to skeletal metastases is one of the common complications
      experienced by the majority of patients suffering from prostate, breast and
      lung cancer at the advanced stage of the disease.
    explanation: This reference supports the statement that bone pain is a common
      complication in advanced lung cancer with skeletal metastases, aligning with
      the note that it may indicate bone metastases.
  phenotype_term:
    preferred_term: Bone Pain
    term:
      id: HP:0002653
      label: Bone pain
- category: Respiratory
  frequency: OCCASIONAL
  name: Chest Pain
  evidence:
  - reference: PMID:27466520
    supports: NO_EVIDENCE
    snippet: The most prevalent symptoms were coughing (EORTC score 41.7), dyspnea
      (33.9), fatigue (31.9), insomnia (30.3) and pain (21.8).
    explanation: The study lists pain as one of the prevalent symptoms but does not
      specify chest pain or its frequency.
  - reference: PMID:20536932
    supports: NO_EVIDENCE
    snippet: Bone cancer pain is common in patients with advanced breast, prostate,
      and lung cancer as these tumors have a remarkable affinity to metastasize to
      bone.
    explanation: The study discusses bone cancer pain in the context of lung cancer
      metastasis but does not mention chest pain or its frequency.
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
- category: Respiratory
  frequency: OCCASIONAL
  name: Recurrent Pneumonia
  notes: Due to airway obstruction by tumor
  evidence:
  - reference: PMID:23857204
    supports: SUPPORT
    snippet: Recurrent pneumonias often occur in the setting of an airway obstruction
      and can be the presenting symptom of an undiagnosed malignancy.
    explanation: The abstract mentions that recurrent pneumonias often occur due to
      airway obstruction, which can be a symptom of lung cancer.
  - reference: PMID:15723108
    supports: SUPPORT
    snippet: Obstruction of the airway should be initially evaluated with endoscopic
      procedures.
    explanation: This reference supports the statement by indicating that airway obstruction,
      which can be caused by tumors, is a concern in respiratory emergencies in cancer
      patients.
  phenotype_term:
    preferred_term: Recurrent Pneumonia
    term:
      id: HP:0006532
      label: Recurrent pneumonia
- category: Neurologic
  frequency: OCCASIONAL
  name: Headache
  notes: May indicate brain metastases
  evidence:
  - reference: PMID:29484515
    supports: PARTIAL
    snippet: However, brain metastasis sometimes occurs in early stage NSCLC patients
      without any neurological symptoms.
    explanation: The reference indicates that brain metastasis can occur in NSCLC
      patients, often without neurological symptoms. However, it does not specifically
      mention headache as an occasional symptom.
  - reference: PMID:11754303
    supports: NO_EVIDENCE
    snippet: Paraneoplastic disorders may affect any part of the central or peripheral
      nervous systems.
    explanation: The reference discusses paraneoplastic disorders affecting the nervous
      system but does not specifically mention headache as a symptom of NSCLC.
  - reference: PMID:15056056
    supports: PARTIAL
    snippet: Brain metastases secondary to primary non-small cell and small cell lung
      cancer have become an important area of research.
    explanation: The reference discusses brain metastases in NSCLC but does not specifically
      mention headache as an occasional symptom.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
biochemical:
- name: Carcinoembryonic Antigen
  synonyms:
  - CEA
  presence: Elevated
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:37390106
    supports: SUPPORT
    snippet: Carcinoembryonic antigen (CEA) is the most frequently used tumor marker
      for non-small cell lung cancer (NSCLC).
    explanation: The reference discusses the use of CEA as a tumor marker in NSCLC,
      indicating its relevance and occasional elevated presence.
- name: Cytokeratin Fragment 21-1
  synonyms:
  - CYFRA 21-1
  presence: Elevated
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:8709175
    supports: SUPPORT
    snippet: The mean (SD) value of serum CYFRA 21-1 in NSCLC (13.26 (16.54)) was
      significantly higher than in benign lung diseases (1.74 (1.55)) (p &lt; 0.0001).
    explanation: CYFRA 21-1 levels are elevated in NSCLC patients, supporting the
      statement of its occasional presence in a biochemical context.
genetic:
- name: EGFR
  association: Activating Mutations
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:23647298
    supports: SUPPORT
    snippet: EGFR mutations are a relatively frequent event in non-small-cell lung
      cancer, generally consisting of exon 19 deletion or exon 21 substitution. In
      adenocarcinoma, additional rare mutations are detectable in the EGFR gene.
    explanation: The reference indicates that EGFR mutations, including activating
      mutations, are a frequent event, which matches the statement that such mutations
      occur occasionally.
  - reference: PMID:27926500
    supports: SUPPORT
    snippet: The results of this study demonstrate that EGFR-TKI therapy results in
      survival benefits for EGFR-mutant advanced NSCLC patients, regardless of gender,
      smoking history, pathologic type, type of EGFR mutations, brain metastasis and
      timing of targeted therapy.
    explanation: This study further supports the association of EGFR activating mutations
      in NSCLC and the effectiveness of targeted therapies, implying the commonality
      and impact of these mutations.
  - reference: PMID:32107398
    supports: SUPPORT
    snippet: EGFR mutation status might be correlated to CT scans imaging phenotypes.
    explanation: The research recognizes the frequent mutations in EGFR, validating
      the association stated in the provided statement.
  - reference: PMID:30520383
    supports: SUPPORT
    snippet: Moreover, 10 to 15% of all NSCLCs harbor EGFR (epidermal growth factor
      receptor) activating mutations.
    explanation: The frequency (10-15%) explicitly mentioned aligns well with the
      occasional occurrence stated in the statement.
  - reference: PMID:18957054
    supports: SUPPORT
    snippet: Somatic mutations in the epidermal growth factor receptor (EGFR) gene
      are associated with the response to EGFR tyrosine kinase inhibitors in patients
      with non-small cell lung cancer.
    explanation: The reference confirms that activating mutations in EGFR are significant
      and frequent enough to impact treatment and response, supporting the statement&#39;s
      claim.
  - reference: PMID:32657049
    supports: SUPPORT
    snippet: We describe the clinical features, genetic profile, and their correlation
      in NSCLC patients... The frequency of mutations in EGFR, MET, and RET were significantly
      higher in nonsmokers than in smokers.
    explanation: By describing EGFR mutations as a notable factor linked with clinical
      and demographic attributes of NSCLC patients, it supports the occasional frequency
      mentioned in the statement.
  - reference: PMID:23621221
    supports: SUPPORT
    snippet: Mutations affecting the epidermal growth factor receptor (EGFR) are good
      predictors of clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in
      patients with non-small cell lung cancer.
    explanation: The study acknowledges the association of EGFR mutations with clinical
      outcomes in NSCLC, supporting the idea of their occasional prevalence.
- name: ALK
  association: Gene Rearrangements
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:30878128
    supports: SUPPORT
    snippet: The ALK receptor tyrosine kinase (ALK) gene encodes a transmembrane protein
      rearranged in 2-7% of non-small cell lung cancer (NSCLC) cases.
    explanation: The literature describes ALK rearrangements occurring in 2-7% of
      NSCLC cases, supporting the statement that ALK rearrangements are occasional
      in frequency in NSCLC.
  - reference: PMID:35986977
    supports: SUPPORT
    snippet: the presence of ALK/ROS rearrangements in our study is associated with
      an approximately threefold to fourfold increase in thrombosis risk in NSCLC
      patients.
    explanation: The mention of ALK rearrangements aligns with the statement indicating
      that they are a recognised genetic association in NSCLC.
  - reference: PMID:36806787
    supports: SUPPORT
    snippet: more commonly recognized alterations (such as KRAS, BRAF, MET and ERBB
      family mutations, or ALK, RET and ROS1 fusions)
    explanation: The literature identifies ALK rearrangements as part of more commonly
      recognized alterations/subtypes in NSCLC, supporting their occasional occurrence.
- name: ROS1
  association: Gene Rearrangements
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:35200557
    supports: SUPPORT
    snippet: ROS-1 rearrangement is found in 0.9-2.6% of non-small-cell lung cancers
      (NSCLCs), mostly lung adenocarcinomas.
    explanation: The literature states that ROS-1 rearrangement occurs in a small
      percentage of NSCLCs, supporting the statement that ROS1 gene rearrangements
      are occasional in NSCLC.
  - reference: PMID:35986977
    supports: SUPPORT
    snippet: ROS and ALK rearrangement is highly associated with TE development, with
      HR of 4.04 ... p = 0.005
    explanation: The literature mentions ROS1 rearrangements in the context of their
      association with thromboembolic events, indicating the presence and relevance
      of these genetic alterations in NSCLC.
  - reference: PMID:34325210
    supports: SUPPORT
    snippet: We investigated the clinical characteristics and gene mutation rate of
      non-small cell lung cancer patients with osteoblastic bone metastases at the
      time of the initial diagnosis. ... two were ROS1 rearrangement-positive.
    explanation: This reference confirms the presence of ROS1 rearrangements in a
      subgroup of NSCLC patients, which aligns with the statement regarding the occasional
      frequency of these rearrangements.
  - reference: PMID:36806787
    supports: SUPPORT
    snippet: Less commonly identified alterations (such as...ROS1 fusions).
    explanation: The literature identifies ROS1 fusions as less common alterations
      in NSCLC, which supports the occasional occurrence of these gene rearrangements.
- name: KRAS
  association: Activating Mutations
  frequency: OCCASIONAL
  notes: Co-mutation with STK11 and/or KEAP1 predicts cold tumor microenvironment
    and inferior response to immune checkpoint inhibitors
  evidence:
  - reference: PMID:33618059
    supports: SUPPORT
    snippet: Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene
      homolog (KRAS) is the most common oncogenic driver in advanced non-small cell
      lung cancer, occurring in approximately 30% of lung adenocarcinomas.
    explanation: This reference confirms that KRAS activating mutations are present
      in non-small cell lung cancer (NSCLC).
  - reference: PMID:23723294
    supports: SUPPORT
    snippet: Although EGFR mutations were most frequent in patients with ADC and never/light
      smokers from Asia, and KRAS mutations were most frequent in patients with ADC
      and ever/heavy smokers from Western countries, both were detected outside these
      subgroups.
    explanation: This reference supports the occurrence of KRAS mutations in NSCLC,
      indicating they are within a notable frequency and linked to specific subgroups.
  - reference: PMID:31862576
    supports: SUPPORT
    snippet: KRAS mutations are one of the most prevalent alterations in non-small
      cell lung cancer.
    explanation: This reference reiterates the frequent nature of KRAS mutations in
      NSCLC, aligning with the &#34;occasional&#34; frequency stated.
- name: STK11
  association: Loss-of-function Mutations
  frequency: OCCASIONAL
  notes: Co-mutation with KRAS creates metabolic dependency on G6PD/PPP pathway; associated
    with cold tumor microenvironment and poor ICI response; dual PD-L1/CTLA-4 blockade
    may partially overcome resistance
- name: KEAP1
  association: Loss-of-function Mutations
  frequency: OCCASIONAL
  notes: Activates NRF2 antioxidant pathway; independent adverse prognostic factor
    for OS on ICIs (HR 1.890); co-mutation with KRAS predicts ICI resistance; dual
    PD-L1/CTLA-4 blockade may provide benefit
- name: TP53
  association: Loss-of-function Mutations
  frequency: FREQUENT
  notes: Independent adverse prognostic factor for OS on ICIs (HR 1.735); associated
    with higher tumor mutational burden; variable impact on ICI outcomes depending
    on co-mutation context
- name: G6PD
  association: Metabolic Dependency
  frequency: OCCASIONAL
  notes: KRAS/LKB1 co-mutant tumors show selective dependency on G6PD for NADPH generation
    and lipogenesis; genetic ablation activates p53 and suppresses tumorigenesis
environmental:
- name: Smoking
  notes: Major risk factor, particularly for squamous cell carcinoma
  evidence:
  - reference: PMID:27188576
    supports: SUPPORT
    snippet: Non-small-cell lung cancer (NSCLC), a heterogeneous class of tumours,
      represents approximately 85% of all new lung cancer diagnoses. Tobacco smoking
      remains the main risk factor for developing this disease.
    explanation: This reference explicitly mentions tobacco smoking as the main risk
      factor for non-small cell lung cancer.
  - reference: PMID:24976334
    supports: SUPPORT
    snippet: The never-smokers had a significantly better prognosis than ever-smokers
      among Ad patients, whereas the light-smokers had a significantly worse prognosis
      than heavy smokers among Sq patients.
    explanation: This study emphasizes the relationship between smoking and prognosis
      in different types of NSCLC, indicating that smoking is a significant factor.
  - reference: PMID:9498897
    supports: SUPPORT
    snippet: Tobacco smoke has been shown to increase the risk of lung cancer down
      to the lowest exposure levels. Environmental tobacco smoke contains the same
      carcinogenic compounds as those found in the tobacco smoke inhaled directly
      by the smoker.
    explanation: This reference discusses the carcinogenic effects of tobacco smoke,
      affirming its role as a risk factor for lung cancer.
  - reference: PMID:34083039
    supports: SUPPORT
    snippet: Smoking is a major risk factor for a variety of diseases, including cancer
      and immune-mediated inflammatory diseases. Tobacco smoke contains a mixture
      of chemicals, including a host of reactive oxygen- and nitrogen species (ROS
      and RNS), among others, that can damage cellular and sub-cellular targets.
    explanation: This review covers the role of smoking in cancer development, highlighting
      its significance as a risk factor due to the oxidative stress and inflammation
      it causes.
  - reference: PMID:19020892
    supports: SUPPORT
    snippet: Arsenic exposure was associated with non-small cell lung cancer. Silicosis
      turned out as major determinant of the cell type related with arsenic.
    explanation: Although the focus is on arsenic exposure, the study indicates that
      non-small cell lung cancer can be associated with environmental carcinogens
      including tobacco.
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
- name: Radon Exposure
  notes: Increases risk, especially in combination with smoking
  evidence:
  - reference: PMID:12075673
    supports: PARTIAL
    snippet: Based on the most recent findings, there is some evidence that radon
      may contribute to lung cancer risk in current smokers in high residential radon
      environments... The situation regarding the risk of lung cancer from radon in
      non-smokers (ex and never) is unclear.
    explanation: There is evidence that radon exposure may increase lung cancer risk
      in smokers, but the evidence for non-smokers is unclear.
  - reference: PMID:38159450
    supports: SUPPORT
    snippet: Miners increased risk of contracting lung cancer is included. It is concluded
      that the mine ventilation system satisfies the conditions required by the current
      radiological protection of the miners.
    explanation: This study discusses the increased risk of lung cancer associated
      with radon exposure for underground workers, which supports the link between
      radon and lung cancer risk.
  - reference: PMID:20429156
    supports: NO_EVIDENCE
    snippet: Environmental factors in cancer... radon.
    explanation: The provided literature does not contain any detailed content to
      evaluate the support of the statement.
  - reference: PMID:25351923
    supports: SUPPORT
    snippet: Human lung cancers are phenotypically more diverse and broadly constitute
      2 types... small cell lung cancers and nonsmall cell lung cancers (NSCLCs).
      ... especially in lung cancers resulting from exposure to environmental carcinogens.
    explanation: The reference supports the association between environmental agents,
      including radon, and non-small cell lung cancer.
  exposure_term:
    preferred_term: Radon exposure
    term:
      id: ECTO:9000097
      label: exposure to radon
treatments:
- name: Surgery
  description: Lobectomy or pneumonectomy for localized disease
  evidence:
  - reference: PMID:11720753
    supports: SUPPORT
    snippet: Surgical resection remains the treatment of choice for early stage non-small
      cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA
      surgical treatment offers the best long-term prognosis when a complete resection
      can be performed. Standard operations include lobectomy, bilobectomy and pneumonectomy.
    explanation: This indicates that lobectomy and pneumonectomy are standard surgical
      treatments for localized non-small cell lung cancer.
  - reference: PMID:37625619
    supports: SUPPORT
    snippet: Lobectomy is the standard treatment for patients with early-stage non-small
      cell lung cancer (NSCLC).
    explanation: This further reinforces that lobectomy, a type of surgery, is a standard
      treatment for localized non-small cell lung cancer.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Chemotherapy
  description: Platinum-based chemotherapy (cisplatin or carboplatin) in combination
    with other agents
  evidence:
  - reference: PMID:12094333
    supports: SUPPORT
    snippet: Platinum-based chemotherapy is considered the standard treatment for
      advanced non-small cell lung cancer (NSCLC). Several phase II trials using cisplatin
      in combination with new chemotherapeutic agents, such as gemcitabine, the taxanes,
      vinorelbine, and irinotecan, showed impressive response rates and suggested
      an improvement in overall survival.
    explanation: This supports the statement that platinum-based chemotherapy (specifically
      cisplatin) in combination with other agents is a treatment for NSCLC.
  - reference: PMID:1329222
    supports: SUPPORT
    snippet: &#39;... carboplatin, either alone or in combination, in five separate phase
      II studies for patients with inoperable non-small cell lung cancer (NSCLC).
      ... Subsequently, combinations of carboplatin/cisplatin, carboplatin/etoposide,
      and carboplatin/vinblastine have been evaluated in similar patient groups.&#39;
    explanation: This supports the statement as it mentions that carboplatin, either
      alone or in combination with other agents, is used in the treatment of NSCLC.
  - reference: PMID:26775594
    supports: SUPPORT
    snippet: Of the 1564 patients who were included in the prospective study, 1520
      received either cisplatin (54%) or carboplatin (46%) in combination with pemetrexed,
      gemcitabine, taxanes or vinorelbine.
    explanation: The study provides evidence that both cisplatin and carboplatin,
      in combination with other agents, are used in the treatment of NSCLC.
  - reference: PMID:35525024
    supports: SUPPORT
    snippet: Platinum-based chemotherapy with or without immunotherapy is the mainstay
      of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a
      molecular driver alteration.
    explanation: The mention of platinum-based chemotherapy (cisplatin or carboplatin)
      as a primary treatment supports the statement.
  - reference: PMID:27166967
    supports: SUPPORT
    snippet: Predicting the feasibility of platinum-based chemotherapy remains an
      important issue in elderly (over 70 years) patients with non-small cell lung
      cancer (NSCLC).
    explanation: This statement supports the use of platinum-based chemotherapy in
      the treatment of NSCLC, emphasizing its importance even in elderly patients.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: Targeted Therapy
  description: Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib,
    gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)
  evidence:
  - reference: PMID:34154330
    supports: SUPPORT
    snippet: The review article presents the current state and development of the
      treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer.
      It focuses on the therapeutic progress of traditionally targeted gene mutations
      EGFR, ALK and ROS1.
    explanation: The reference discusses EGFR, ALK, and ROS1 inhibitors as targeted
      therapies for non-small cell lung cancer.
  - reference: PMID:15946581
    supports: SUPPORT
    snippet: The epidermal growth factor receptor (EGFR) is a promising target in
      the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently
      erlotinib and gefitinib are approved by the US Food and Drug Administration.
    explanation: The reference discusses erlotinib and gefitinib as EGFR inhibitors
      used in the treatment of non-small cell lung cancer.
  - reference: PMID:22932130
    supports: SUPPORT
    snippet: Both erlotinib and crizotinib have been shown to be effective and safe
      for subgroup populations, and now personalized treatment for nonsquamous NSCLC
      has progressed even further.
    explanation: The reference confirms the use of erlotinib (EGFR inhibitor) and
      crizotinib (ALK and ROS1 inhibitor) in targeted therapy for non-small cell lung
      cancer.
  - reference: PMID:25240504
    supports: SUPPORT
    snippet: The availability of ... the EGFR-tyrosine kinase inhibitors erlotinib,
      gefitinib, afatinib as well as ... the ALK-inhibitor crizotinib has recently
      changes the treatment algorithm of advanced non-small cell lung cancer.
    explanation: The reference mentions the use of EGFR inhibitors (erlotinib, gefitinib)
      and ALK inhibitor (crizotinib) in treating non-small cell lung cancer.
  - reference: PMID:25322323
    supports: SUPPORT
    snippet: The treatment of patients with advanced non-small cell lung cancer (NSCLC)
      harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has
      been revolutionized by the development of crizotinib, a small molecule inhibitor
      of the tyrosine kinases ALK, ROS1, and MET.
    explanation: The reference discusses crizotinib as an ALK and ROS1 inhibitor used
      in the treatment of non-small cell lung cancer.
  - reference: PMID:27491402
    supports: SUPPORT
    snippet: &#39;Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK
      inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced
      NSCLC outcomes.&#39;
    explanation: The reference supports the use of EGFR inhibitors (erlotinib, gefitinib)
      and ALK inhibitors (crizotinib, ceritinib) in the treatment of non-small cell
      lung cancer.
  - reference: PMID:34125313
    supports: SUPPORT
    snippet: &#39;Four FDA-approved drugs have significant activity against ROS1+ NSCLC:
      crizotinib, ciritinib, lorlatinib, and entrectinib.&#39;
    explanation: The reference mentions crizotinib among the ROS1 inhibitors used
      for treating non-small cell lung cancer.
  - reference: PMID:28089942
    supports: SUPPORT
    snippet: Nowadays, different EGFR TKIs as afatinib, erlotinib and gefitinib are
      approved worldwide for the treatment of NSCLC harbouring EGFR mutations, in
      particular exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations.
    explanation: The reference discusses the use of EGFR inhibitors (erlotinib, gefitinib)
      in the treatment of non-small cell lung cancer.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Immunotherapy
  description: Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high
    PD-L1 expression
  evidence:
  - reference: PMID:28059852
    supports: SUPPORT
    snippet: In accordance with recent results, US Food and Drug Administration approved
      a checkpoint inhibitor for first-line treatment of metastatic non-small cell
      lung cancer whose tumors have high PD-L1 expression, and European Medicines
      Agency approval is expected in early 2017.
    explanation: The FDA has approved immune checkpoint inhibitors for first-line
      treatment of metastatic NSCLC with high PD-L1 expression, supporting the use
      of immunotherapy (including nivolumab and pembrolizumab) for these patients.
  - reference: PMID:26927720
    supports: SUPPORT
    snippet: Data so far available show some conflicting results, but PD-L1 immunohistochemistry
      looks likely to be introduced into clinical use for selecting patients for treatment
      with anti-PD-1 or anti-PD-L1 therapies.
    explanation: The mention of PD-L1 immunohistochemistry being introduced for clinically
      selecting patients for anti-PD-1 therapies supports the statement.
  - reference: PMID:32189549
    supports: PARTIAL
    snippet: A subset of patients who were treated beyond progression with ICI achieved
      a clinically meaningful response with durable disease control.
    explanation: While it shows the effectiveness of checkpoint inhibitors, it is
      about treatment beyond progression and does not specifically address high PD-L1
      expression.
  - reference: PMID:29140105
    supports: PARTIAL
    snippet: Single-agent durvalumab showed clinical efficacy and a manageable safety
      profile in advanced non-small-cell lung cancer, particularly the &gt;/=25% PD-L1+
      population.
    explanation: This supports the efficacy of durvalumab particularly in PD-L1+ populations
      but does not specifically mention nivolumab or pembrolizumab.
  - reference: PMID:33306411
    supports: PARTIAL
    snippet: For the majority of patients, ICIs are cost-effective for lung cancer
      management.
    explanation: This supports the efficacy of ICIs but does not specifically address
      tumors with high PD-L1 expression.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Radiation Therapy
  description: Used for localized disease, palliation of symptoms, or brain metastases
  evidence:
  - reference: PMID:7540125
    supports: PARTIAL
    snippet: recent notable developments have occurred involving radiation therapy
      (RT) for patients with non-small cell lung cancer (NSCLC)... For palliation
      of tumor-related symptoms... metastases to the adrenal gland, liver, and subcutaneous
      tissues can be palliated successfully by brief courses of RT. Intrathoracic
      tumor symptoms are well palliated by brief courses of thoracic RT.
    explanation: Supports the use of RT for palliation of symptoms and metastatic
      sites, but does not specifically mention its use for localized disease.
  - reference: PMID:8853542
    supports: PARTIAL
    snippet: In the palliation of non-small cell lung cancer... in the management
      of chest disease, bone metastases, and brain metastases.
    explanation: Supports the use of RT in palliation of symptoms and brain metastases.
  - reference: PMID:32140986
    supports: SUPPORT
    snippet: Concurrent chemoradiation is the cornerstone of treatment of unresectable,
      locally advanced NSCLC.
    explanation: Supports the use of RT for locally advanced (localized) disease.
  - reference: PMID:30441934
    supports: SUPPORT
    snippet: Radiotherapy should also be considered for locally advanced disease.
    explanation: Supports the use of RT for locally advanced (localized) disease.
  - reference: PMID:27467543
    supports: SUPPORT
    snippet: Stereotactic body radiation therapy has been increasingly used to safely
      deliver LAT and provide high local control in nonoperable non-small-cell lung
      cancer patients.
    explanation: Supports the use of RT for localized disease particularly in nonoperable
      cases.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
datasets:
# NSCLC single-cell RNA-seq tumor microenvironment
- accession: geo:GSE131907
  title: Single cell RNA sequencing of lung adenocarcinoma
  description: &gt;-
    Large-scale single-cell RNA sequencing from 11 adjacent normal and
    15 tumor tissue samples from NSCLC patients (stages I-IV). After
    quality filtering, 98,504 cells retained including 16,046 epithelial,
    5,468 stromal, and 76,990 immune cells.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_types:
    - preferred_term: lung tumor tissue
      tissue_term:
        preferred_term: lung
        term:
          id: UBERON:0002048
          label: lung
  sample_count: 26
  conditions:
    - NSCLC tumor tissue
    - adjacent normal lung tissue
  notes: &gt;-
    Comprehensive single-cell atlas identifying eight major cell types.
    Resolves tumor-infiltrating immune cell heterogeneity relevant to
    immunotherapy response. Part of integrated NSCLC scRNA-seq resource.

# NSCLC single-cell transcriptome heterogeneity
- accession: geo:GSE119911
  title: Comprehensive transcriptomic profiles of non-small cell lung cancer by single-cell RNA-seq
  description: &gt;-
    Single-cell RNA sequencing profiling over 9,000 individual cells
    from tumor and adjacent normal tissues of 20 patients with
    stage I-IV NSCLC using modified STRT-seq technique.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_types:
    - preferred_term: lung tumor tissue
      tissue_term:
        preferred_term: lung
        term:
          id: UBERON:0002048
          label: lung
  sample_count: 106
  conditions:
    - NSCLC tumor tissue
    - adjacent normal tissue
  notes: &gt;-
    Characterizes inter-patient and intra-tumor heterogeneity including
    epithelial, stromal, and immune cell compartments. Useful for
    understanding cancer progression and therapeutic strategies

disease_term:
  preferred_term: non-small cell lung carcinoma
  term:
    id: MONDO:0005233
    label: non-small cell lung carcinoma

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
    - classification_value: cancer
    - classification_value: solid tumor</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Non-Small_Cell_Lung_Cancer.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>